Larvol Veri

CANCER:

Colorectal Adenocarcinoma

Related cancers:

‹

›

PIK3CA V955G PIK3CA V955G	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
ALK fusion ALK fusion	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
KRAS mutation KRAS mutation	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3
EWSR1 mutation EWSR1 mutation	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
PD-L2 overexpression PD-L2 overexpression	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + PD-L2 inhibitor Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and